TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03656029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Participants will smoke as much of the cigarette as they wish

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Participants will smoke as much of the cigarette as they wish

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Participants will smoke as much of the cigarette as they wish

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will smoke a placebo cigarette
Study: NCT04762732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT
Description: Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional wound care
Description: Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
Study: NCT04701177

Intervention type: DIAGNOSTIC_TEST
Intervention: AltoidaML
Description: Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529

Intervention type: DIAGNOSTIC_TEST
Intervention: AltoidaML
Description: Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529

Intervention type: DIAGNOSTIC_TEST
Intervention: AltoidaML
Description: Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529
Study: NCT05351359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: A mHealth-enabled just-in-time adaptive intervention that is based on the HealthReact system developed by the participating centre at the Faculty of Science of the University of Hradec Kralove. The HealthReact system consists of a server-side application that is connected to the Fitbit server. As such, the system allows for just-in-time text messages triggered by pre-defined context as recorded by the Fitbit wearable monitor. For example, a prompt to take a break from sedentary behaviour can be triggered after 30 sedentary minutes, a suggestion to increase walking cadence can be triggered when continuous, but slow walking is detected, or a motivational message with a specific goal to take more steps to reach their usual daily step count can be triggered when the total daily steps are too low. The mHealth component will be delivered for the entire duration of the study (i.e., 12 months).
Study: NCT05665894

Intervention type: DEVICE
Intervention: Hematoma Vaacum Assisted Biopsy
Description: The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
Study: NCT05850949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Konjac Grain
Description: Without supplementation, followed by Supplementation with Dietary Fibre the Konjac-Grain week 1, repeated until week 6, blood collected with a fine needle 10ml citrate-Tube Glucose was measured with disposable 'test-strip', which is then inserted into an electronic blood glucose meter (device: Accu-Check Instant S Glucose from Roche) . Normal value:70 to 99 mg/dL (3.9 to 5.5 mmol/L). Further HbA1c (glycated Hemoglobin A1c) concentration was checked with disposable 'test-strip', which is then inserted into an electronic HbA1c meter (device: Accu-Check Instant S HbA1c from Roche). Unit value fir HbA1c = mg/dl
Study: NCT04550637

Intervention type: DRUG
Intervention: Oral apixaban
Description: apixaban (5 mg bid) is given until 12 weeks after surgery
Study: NCT05170451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Topical CBD 50 mg/ml applied in 1mL amounts twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Topical CBD 50 mg/ml applied in 1mL amounts twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Topical shea butter applied in 1mL amounts twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Topical shea butter applied in 1mL amounts twice daily
Study: NCT06383832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets oral 10mg/d qd, intervention for 12 weeks.
Study: NCT06015386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inclined plane
Description: 2 parallel groups one treated with clear aligner and other treated using inclined plane

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clear aligner
Description: 2 parallel groups one treated with clear aligner and other treated using inclined plane
Study: NCT05351359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone counselling
Description: Regular monthly phone calls by trained counsellors support participants in their effort to increase physical activity and reduce sedentary behaviours. The counsellors will use various behaviour change techniques, such as goal-setting, feedback, action planning, etc. The phone counselling will be provided during the first six months, i.e. 6 phone calls will be delivered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit tracker
Description: Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.
Study: NCT06027866

Intervention type: DEVICE
Intervention: SRAVI (Speech Recognition Application for the Voice Impaired)
Description: Speech Recognition Application for the Voice Impaired (SRAVI) is a novel communication aid developed by Liopa (a company formed by Queen's University Belfast (QUB) and the Centre for Security Information Technologies (CSIT), QUB). SRAVI is an application-based lip-reading system, and the application ('app') can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). When the device is held in front of a patient, it will track lip movement and identify phrases being mouthed.
Study: NCT05616468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGT007 Cell Injection
Description: BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Study: NCT05711043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic sutured gastroplasty with endomina
Description: Subjects in the intervention group will be treated with an ESG with the endomina ® and TAPES devices (Endo Tools Therapeutics S.A.), both CE-marked for endoscopic gastroplasty. The endomina is a device that can be attached to an endoscope and allows remote actuation of the device during a peroral intervention. Thanks to a therapeutic channel that can be angled perpendicularly to the axis of vision of the endoscope, it allows the possibilities of making transoral full thickness tissue apposition and performing, via a transoral route, large plications with tight serosa to serosa apposition in the stomach. This suturing will be done from the incisura to the upper body of the stomach, along the great curvature with TAPES, a single use needle preloaded with suture.~In addition to the endomina device, any other required endoscopic accessories can be used during the procedure (e.g., grasping forceps, loop cutter).
Study: NCT05189548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
Description: A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
Study: NCT05351359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit tracker
Description: Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brief advice
Description: A brief advice will be provided by the general practitioner at the start of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief advice
Description: A brief advice will be provided by the general practitioner at the start of the study.
Study: NCT05353595

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Insect protein
Description: Insect protein concentrate retrieved from lesser mealworms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Running exercise
Description: 40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Running exercise
Description: 40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
Study: NCT05936008

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise MICT
Description: Standard of care, exercise recommendations for people with stroke

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise HIIT
Description: The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
Study: NCT05444218

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open flap debridement
Description: After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
Study: NCT04899843

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulphate tablet 20 mg
Description: Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet 20 mg
Description: Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
Study: NCT05077800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRNINOX
Description: Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRNINOX
Description: Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRNINOX
Description: Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRNINOX
Description: Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRNINOX
Description: Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Taken Orally
Study: NCT05444218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Er: YAG irradiation
Description: An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Er: YAG irradiation
Description: An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (beginning after open flap debridement).
Study: NCT05077800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Administered by intravenous infusion
Study: NCT06289933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR3005
Description: One tablet administered alone, Once a day
Study: NCT04835337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air Purifiers
Description: Students are divided into two groups: intervention group and control group. The intervention team places an air purifier in the indoor environment to intervene. All the indoor environment of the group use the same qualified air purifier, and all participants and research staffs are blinded to the group assignment.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Air Purifiers
Description: The control group is also intervened. The intervention is to place a sham air purifier (remove the filter screen) in the indoor environment, and all the indoor environment use the same air purifier as the intervention group. All participants and research staffs are blinded to the group assignment.
Study: NCT06155227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise combined with blood flow restriction
Description: aerobic exercise combined with blood flow restriction for 18 sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic exercise for 18 sessions
Study: NCT04955340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-resminostat
Description: 1 single dose of 400 mg \[14C\]-resminostat
Study: NCT06079125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression with duraplasty
Description: The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFDD with tonsillar resection/reduction
Description: The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.
Study: NCT06479616

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CS-101
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study: NCT04797650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTP-543 matching placebo
Description: Administered as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as tablets.
Study: NCT06289933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR3005-1
Description: One tablet administered alone, Once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR3005-2
Description: One tablet administered alone, Once a day
Study: NCT05418322

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Oral Hygiene Intervention
Description: The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Oral Hygiene Intervention
Description: The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.
Study: NCT03620266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberry
Description: The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioprocessed oat bran
Description: The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination bilberry/oats
Description: The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.